Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Thomas Jefferson University
Eastern Cooperative Oncology Group
University of Wisconsin, Madison
Stanford University
University of Kansas Medical Center
Roswell Park Cancer Institute
Fox Chase Cancer Center
University of Arizona
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)